Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Diffusion Pharmaceutics ($DFFN) stock reacted positively to the news of the company achieving drug production milestone for its planned Phase 3 trial. The company completed a major production run of its lead drug candidate trans sodium crocetinate (TSC). The produced quantity is sufficient to support the entire trial. The company said that the FDA required it to use the drug which was made using commercially-ready processes. Diffusion is now collaborating with the FDA for designing and executing the planned Phase 3 study. The trials are expected to be started by the end of this year.
The company stock gained over 10 percent in its previous trading session, trimming its Year to Date losses to 46.5 percent.

BiondVax Pharmaceuticals ($BVXV) announced positive results for its Phase 2b clinical trials for universal flu vaccine. The data showed statistically significant positive results for M-001, the company's universal flu vaccine candidate. The study met both its primary endpoints which were Safety and influenza-specific cellular immune responses. The company also reported that M-001 has a good safety profile and is well-tolerated. The study found statistically significant elevated T-cell dependent immune responses in both dosage forms, especially in the 1.0mg dose group.
The company stock has shown good performance as it gained over 194 percent this year so far while its 12 months gain stands at 166 percent.


Amgen ($AMGN) announced receiving the FDA acceptance of its Biologics License Application (BLA) seeking approval of Aimovig (erenumab) for the prevention of migraine in patients experiencing at least four migraine days per month. The company will collaborate with Novartis for commercializing the drug in the US.

Insulet ($PODD) announced that it will take control of sales and marketing activities for its Omnipod System in Europe. The company will also manage the distribution and other support activities. Insulet reported that the change will be effective from June 30, 2018 when its current contract with Ypsomed AG expires.

DarioHealth ($DRIO) announced receiving the 510(k) clearance from the FDA for its app. The approval will help the company in expanding the reach of its Dario Blood Glucose Monitoring System as currently it is only available on iOS operating system.

Masimo ($MASI) announced receiving the CE marking for RPVI, which is a measure for the dynamic changes in perfusion index that occur during the respiratory cycle. RPVI is designed to provide enhanced specificity to changes in fluid volume.


iKang Healthcare Group ($KANG) announced a new cooperative arrangement with China Industrial Asset Management. The arrangement entails forming healthcare focused investment fund which will provide financing to various medical centers.

Exelixis ($EXEL) announced reaching a settlement with Genentech regarding their collaboration agreement for cancer med COTELLIC (cobimetinib). Both the parties have agreed to revise their revenue and cost-sharing arrangements.

Brokerage Action Company Rating
HC Wainwright Reiterates Caladrius Biosciences (CLBS)
KeyCorp Reiterates Cooper Companies, Inc. (The) (COO)
Overweight -> Sector Weight
Needham & Company LLC Initiates Express Scripts Holding Company (ESRX)
Hold -> Hold
Goldman Sachs Group, Inc. (The) Downgrades FibroGen (FGEN)
Buy -> Neutral
Jefferies Group LLC Reiterates Henry Schein (HSIC)
J P Morgan Chase & Co Reiterates Ironwood Pharmaceuticals (IRWD)
Overweight -> Neutral
J P Morgan Chase & Co Reiterates Intuitive Surgical (ISRG)
Barclays PLC Raises Target Intuitive Surgical (ISRG)
Cantor Fitzgerald Reiterates Intuitive Surgical (ISRG)

Gainers (% price change)Last TradeChangeMkt CapSarepta Therapeutics IncSRPT40.93+6.85 (20.10%)2.26BBioDelivery Sciences IntlBDSI3.15+0.15 (5.00%)171.42MSimulations Plus, Inc.SLP15.15+0.70 (4.84%)273.57MCatalyst PharmaceuticalsCPRX3.05+0.12 (4.10%)280.43MThe Medicines CompanyMDCO39.08+1.46 (3.88%)2.81BLosers (% price change)Ironwood PharmaceuticalsIRWD17.00-1.55 (-8.36%)2.50BAccelerate DiagnosticsAXDX27.65-1.35 (-4.66%)1.50BPacific Biosciences ofPACB3.20-0.14 (-4.19%)324.39MAVEO Pharmaceuticals, IncAVEO2.52-0.11 (-4.18%)312.58MBioScrip IncBIOS2.89-0.09 (-3.02%)354.40MMost Actives (dollar volume)Sarepta Therapeutics IncSRPT40.93+6.85 (20.10%)2.26BJohnson & JohnsonJNJ136.57+1.36 (1.01%)369.95BVertex PharmaceuticalsVRTX159.33-0.36 (-0.23%)47.95BGilead Sciences, Inc.GILD73.42+0.70 (0.96%)97.32BAbbott LaboratoriesABT50.85+1.39 (2.81%)89.49B